SynthesisJournal of cancer research and clinical oncology2023

PARP inhibitors and overall survival in ovarian cancer, reevaluation advised in all settings.

Timothée Olivier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.